Pharmacological treatment: Of alcohol dependence - A review of the evidence

JAMA

Volumn 281, Issue 14, 1999, Pages 1318-1325

  Garbutt, James C ^b   West, Suzanne L ^a   Carey, Timothy S ^b   Lohr, Kathleen N ^b   Crews, Fulton T ^b  

^a RTI INTERNATIONAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; BUSPIRONE; CITALOPRAM; DISULFIRAM; FLUOXETINE; FLUVOXAMINE; LITHIUM; NALMEFENE; NALTREXONE; ONDANSETRON;

ADDICTION; ADULT; ALCOHOLISM; CHRONIC DISEASE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; REVIEW;

EID: 0033553203     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.14.1318     Document Type: Review

References (61)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
2. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA. 1990;264:2511-2518.
3. Grant BF. Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States. J Stud Alcohol. 1997;58:464-473.
4. Grant BF, Harford TC, Dawson DA, Chou P, Dufour M, Pickering R. Prevalence of DSW-IV alcohol abuse and dependence: United States, 1992. Alcohol Health Res World. 1994;19:243-248.
5. Caetano R, Tam TW. Prevalence and correlates of DSM-IV and ICD-10 alcohol dependence. Alcohol Alcohol. 1995;30:177-186.
6. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA. 1993;270:2207-2212.
7. National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA). The Economic Costs of Alcohol and Drug Abuse in the United States, 1992. Bethesda, Md: National Institutes of Health, US Dept of Health and Human Services; 1998.
8. Mayo-Smith MF, for the American Society of Addiction Medicine Working Group for Practice Guideline on Pharmacological Management of Alcohol Withdrawal. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA. 1997;278;144-151.
9. West SL, Garbutt JC, Carey TS, et al. Pharmacotherapy for Alcohol Dependence: evidence Report No. 3. Rockville, Md: Agency for Health Care Policy and Research; 1999. AHCPR publication 99-E004.
10. Fuller RK, Roth HP. Disulfiram for the treatment of alcoholism. Ann Intern Med. 1979;90:901-904.
11. Fuller R, Roth H, Long S. Compliance with disulfiram treatment of alcoholism. J Chronic Dis. 1983; 36:161-170.
12. Schuckit MA. A one-year follow-up of men alcoholics given disulfiram. J Stud Alcohol. 1985;46: 191-195,
13. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. JAMA. 1986;256: 1449-1455.
14. Chick J, Cough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry. 1992;161:84-89.
15. Bischof T, Bucher J, Battig B, Frei A. Disulfiram in the treatment of alcoholic patients [in German]. Schweiz Rundsch Med Prax. 1995;84:698-702.
16. Whyte CR, O'Brien PM. Disulfiram implant: a controlled trial. Br J Psychiatry. 1974;124:42-44.
17. Wilson A, Davidson WJ, White J. Disulfiram implantation: placebo, psychological deterrent, and pharmacological deterrent effects. Br J Psychiatry. 1976; 129:277-280.
18. Wilson A, Davidson WJ, Blanchard R, White J. Disulfiram implantation. J Stud Alcohol. 1978;39:809-819.
19. Wilson A, Davidson WJ, Blanchard R. Disulfiram implantation: a trial using placebo implants and two types of controls. J Stud Alcohol. 1980;41:429-436.
20. Johnsen J, Stowell A, Bache-Wiig JE, et al. A double-blind placebo controlled study of male alcoholics given a subcutaneous disulfiram implantation. Br J Addict. 1987;82:607-613.
21. Johnsen J, Morland J. Disulfiram implant: a double-blind placebo controlled follow-up on treatment outcome. Alcohol Clin Exp Res. 1991;15:532-536.
22. O'Malley SS, Jaffe A, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881-887.
23. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
24. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54:737-742.
25. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCI for alcohol dependence. Alcohol Clin Exp Res. 1994;18:1162-1167.
26. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry. 1995;152:613-615.
27. Volpicelli JR, Clay KL, Watson NT, O'Brien CP. Naltrexone in the treatment of alcoholism. J Clin Psychiatry. 1995;56:39-44.
28. O'Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy foralcohol dependence. Arch Gen Psychiatry. 1996;53:217-224.
29. O'Malley SS, Jaffe AJ, Rode S, Rounsaville BJ. Experience of a "slip" among alcoholics treated with naltrexone or placebo. Am J Psychiatry. 1996;153:281-283.
30. O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol. 1996;13:35-39.
31. Gerra G, Caccavari R, Delsignore R, Bocchi R, Fertonani F, Passeri M. Effects of fluoxetine and caacetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients. Curr Ther Res. 1992; 52:291-295.
32. Ladewig D, Knecht T, Leher P, Fendl A. Acamprosate: a stabilizing factor in long-term withdrawal of alcoholic patients [in German]. Ther Umsch. 1993; 50:182-188.
33. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30:239-247.
34. Roussaux JP, Hers D, Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics? [in French]. J Pharm Belg. 1996;51:65-68.
35. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Arch Gen Psychiatry. 1996;53:673-680.
36. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;347:1438-1442.
37. Geerlings PJ, Ansoms C, Van den Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res. 1997;3:129-137.
38. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. Br J Psychiatry. 1997;170:73-77.
39. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction. 1997;92:1537-1546.
40. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res. 1992;16:261-265.
41. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152: 391-397.
42. Janiri L, Gobbi G, Mannelli P, Pozzi G, Serretti A, Tempesta E. Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol. 1996;11:109-117.
43. Kabel DI, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: Alcohol Clin Exp Res. 1996;20:780-784.
44. Kranzler HR., Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20:1534-1541.
45. 3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994;18:879-885.
46. Tiihonen J, Ryynanen OP, Kauhanen I, Hakola HP, Salaspuro M. Citalopram in the treatment of alcoholism. Pharmacopsychiatry. 1996;29:27-29.
47. Malec E, Malec T, Gagne MA, Dongier M. Buspirone in the treatment of alcohol dependence. Alcohol Clin Exp Res. 1996;20:307-312.
48. Malcolm R, Anton RF, Randall CL, et al. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res. 1992;16:1007-1013.
49. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics. Arch Gen Psychiatry. 1994;51:720-731.
50. Cornelius JR, Saltoum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54:700-705.
51. Kline NS, Wren JC, Cooper TB, Varga E, Canal O. Evaluation of lithium therapy in chronic and periodic alcoholism. Am J Med Sci. 1974;268:15-22.
52. Merry J, Reynolds CM, Bailey J, Coppen A. Prophylactic treatment of alcoholism by lithium carbonate. Lancet. 1976;1:481-482.
53. Pond SM, Becker CE, Vandervoort R, et al. An evaluation of the effects of lithium in the treatment of chronic alcoholism, I: Alcohol Clin Exp Res. 1981; 5:247-251.
54. Fawcett J, Clark DC, Gibbons RD, et al. Evaluation of lithium therapy for alcoholism. J Clin Psychiatry. 1984;45:494-499.
55. Fawcett J, Clark DC, Aagesen CA, et al. A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry. 1987; 44:248-256.
56. de la Fuente JR, Morse RM, Niven RG, Ilstrup DM. A controlled study of lithium carbonate in the treatment of alcoholism. Mayo Clin Proc. 1989;64:177-180.
57. Clark DC, Fawcett J. Does lithium carbonate therapy for alcoholism deter relapse drinking? Recent Dev Alcohol. 1989;7:315-328.
58. Dorus W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA. 1989;262:1646-1652.
59. Pisani VD, Fawcett J, Clark DC, McGuire M. The relative contributions of medication adherence and AA meeting attendance to abstinent outcome for chronic alcoholics. J Stud Alcohol. 1993;54:115-119.
60. Croop RSM, Faulkner EB, Labriola DFP, for the Naltrexone Usage Study Group. The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry. 1997;54:1130-1135.
61. Brewer C. Recent developments in disulfiram treatment. Alcohol Alcohol. 1993;28:383-395.